CDChristophe Debuy

Christophe Debuy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christophe Debuy has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Désirée Y. van Haaften-Visser

    Centre of Lysosomal and Metabolic Diseases, Department of Paediatrics Erasmus Medical Centre Rotterdam the Netherlands

    2 shared publications
  • Alice S. Brooks

    Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    1 shared publication
  • Bastiaan T. van Dijk

    Department of Paediatrics, Willem-Alexander Children’s Hospital, Division of Neonatology, Leiden University Medical Centre, Leiden, the Netherlands

    1 shared publication
  • Bianca M. de Graaf

    Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    1 shared publication
  • C. J. Klein‐De Ronde

    Centre of Lysosomal and Metabolic Diseases, Department of Clinical Genetics Erasmus Medical Centre Rotterdam the Netherlands

    1 shared publication
  • D. Vos

    Centre of Lysosomal and Metabolic Diseases, Department of Clinical Genetics Erasmus Medical Centre Rotterdam the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Bringing Untargeted Metabolomics to the Clinic: Real‐World Data and Implementation for Screening of Inherited Metabolic Diseases

    by D. Augustijn, R. Bonte, M. C. Hagemeijer, J. Bierau, E. H. Jacobs, C. J. Klein‐De Ronde, E. van der Star, D. Y. van Haaften‐Visser, N. C. Peltenburg‐De Jong, C. Debuy, et al.

    Inherited metabolic diseases (IMD) require timely diagnosis since a considerable number of these disorders respond to early treatment. Traditional metabolic screening relies on multiple targeted assays guided by clinical symptoms, making it laborious and potentially increasing the risk of underdiagnosis. Untargeted metabolomics provides broader biochemical coverage, but evidence of its diagnostic performance is limited. In this metabolomics implementation study, we analysed 484 plasma samples submitted for routine metabolic screening using both targeted assays and metabolomics in parallel. The results of these analyses were independently interpreted by two laboratory specialists and results were compared. Overall, 85.5% concordance was achieved between the two approaches. The majority of discrepancies stem from aberrant biomarkers traditionally measured in urine observed in metabolomics but not in the targeted plasma analyses. Importantly, inconclusive results requiring follow up were equally observed among the two methods. Metabolomics screening resulted in the detection of one new and one tentative IMD, which were not detected by targeted tests. Collectively, these results support the application of untargeted metabolomics for IMD screening in clinical practice. In addition to our study results, we share our detailed protocol and workflow towards implementation of untargeted metabolomics in clinical practice to facilitate broader use of diagnostic metabolomics in the IMD community.

  • Open Access

    Nanopore long-read sequencing for the critically ill facilitates ultrarapid diagnostics and urgent clinical decision making

    by Daphne J. Smits, Federico Ferraro, Mark Drost, Herma C. van der Linde, Bianca M. de Graaf, Yolande van Bever, Alice S. Brooks, Livija Bardina, Hennie T. Brüggenwirth, Christophe Debuy, et al.

    Critically ill pediatric patients often have genetic disorders requiring a rapid diagnosis to guide urgent care decisions. Standard genetic testing typically takes weeks and requires multiple tests. Nanopore long-read genome sequencing (LR-GS) delivers genome-wide results within days as a one-test-fits-all solution. As one of the first centers in Europe, we implement ultrarapid LR-GS for critically ill patients. We enrolled 26 critically ill patients (median age 2 months) suspected of having a genetic disorder at the intensive care unit to perform (ultra)rapid nanopore LR-GS alongside standard genomic care. We compared diagnostic yield, turnaround time (TAT), and evaluated the impact on clinical decision making. In 11/26 cases a genetic diagnosis was made with (ultra)rapid LR-GS. From sample receipt to result, the average TAT was 5.3 days (range 2.0–10.8) for LR-GS and 18.4 days (range 6.1–29.1) for standard genomic care. DNA methylation analysis from LR-GS expedited the diagnosis in 3/26 cases. In 7/11 solved cases ultrarapid LR-GS led to immediate adjustments in patient care, e.g., medication switch or termination of treatment. Our findings underscore the clinical impact of ultrarapid LR-GS, including added value of methylation analysis, for critically ill patients and highlight existing challenges, paving the way to ultrarapid LR-GS integration into standard diagnostics.